A FTSE 250 growth share I’d buy to target a multibagger return

I’ve been looking for a FTSE 250 growth stock to add to my 2024 Stocks and Shares ISA. I think I might have found it.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Buying FTSE 250 shares can sometimes give us a white-knuckle ride. But then, the mid-cap index has trounced the FTSE 100 in long-term returns.

We’re looking at a long-term average return from the smaller index of around 11% per year, against closer to 7%.

FTSE 250 stocks have been falling back again in the past few years, but they’re starting to make gains once more.

Should you invest £1,000 in J D Wetherspoon Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if J D Wetherspoon Plc made the list?

See the 6 stocks

FTSE 250 growth

There are some big dividends from the FTSE 250, but today I have my eye on a pure growth stock.

It’s biotech research firm PureTech Health (LSE: PRTC). And its share price over the past five years has been… how pale are those knuckles again?

Created with Highcharts 11.4.3PureTech Health Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Explosive growth?

Let’s look at an obvious negative. PureTech is not producing regular profit, and forecasts don’t show any in the next couple of years.

But, the company has just completed a share buyback to the tune of $100m. Isn’t it a bit strange for a company that’s not in profit to be returning cash? Well, yes.

But the $14bn sale of the PureTech-founded Karuna Therapeutics to Bristol Myers Squibb made a big difference to the cash pile.

And at the end of the last full year on 31 March, the company reported cash, equivalents, and short-term investments of $573m. The board reckons there’s enough to keep it going for the next few years.

Clinical research

The future is all about the possibilities for PureTech’s research. It specialises in medicines related to the brain, gut, and immune system. And it has a number of candidates making their way through the regulatory systems in the EU and the US.

As well as it’s own research, PureTech has fingers in a lot of other pies, through its ‘Founded Entities’ approach… like that Karuna success.

It has stakes in a range of firms, working in the neuropsychiatric, oncology, immunology, and other fields.

The way forward

It’s all down to hopes for PureTech’s research pipeline, and those of its Founded Entities. But for me, I see the approach here as more attractive than most in this business.

Speaking of the firm’s internal research targets, CEO Bharatt Chowrira spoke of the options open to advance them.

He spoke of “progressing them in Founded Entities or through partnerships” as one way. And when the firm launches a new firm like this, they’ve recently been oversubscribed.

Oh, and the CEO also pointed out that “We take great pride in our track record of clinical success, which is six times the industry average“.

A buy?

Buying PureTech Health shares now would be very speculative. We just don’t have the usual measures to value it. There’s no useful price-to-earnings (P/E) ratio, no dividend yield, etc.

But, analysts do expect strong sales from PureTech in the next couple of years.

It’s tricky weighing this against the other stocks on my wanted list. But if I buy, it’ll only be small amount, as there’s a chance of losing it. But if it comes good, I might hope for a multibagger here.

But there may be an even bigger investment opportunity that’s caught my eye:

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 shares I’ve bought in the 2025 stock market sell-off

The stock market has experienced a lot of turbulence in recent weeks. Edward Sheldon has been taking advantage and buying…

Read more »

Investing Articles

Investors considering HSBC shares could aim for £8,453 a year in passive income from just £5 a day!

A relatively small daily investment in HSBC shares over several years can produce an extraordinary level of annual passive income…

Read more »

Investing Articles

The Rolls-Royce share price has fallen! Is this the moment investors have been waiting for?

Even the Rolls-Royce share price can't escape current stock market volatility, falling slightly over the last week. Should investors consider…

Read more »

Modern suburban family houses with car on driveway
Investing Articles

Down 59% from its 12-month highs, is this FTSE 250 stock too cheap to ignore?

Shares in FTSE 250 housebuilder Vistry are almost certainly too cheap to ignore. But are they discounted enough to offset…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

As the S&P 500 struggles to recover, here’s what Warren Buffett’s doing

The S&P 500 is fighting to regain its February highs amid ongoing trade tariff uncertainty. Our writer looks to the…

Read more »

Investing Articles

When will Lloyds shares hit £1?

Lloyds shares have surged over the past 12 months, but where will they go next? Dr James Fox thinks there’s…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Stock-market crash: the meltdown of the Magnificent 7

Just before Christmas, these Magnificent Seven stocks were riding high. But after the worst quarter for US stocks since autumn…

Read more »

Investing Articles

Wow! IAG shares are undervalued by 47%, according to analysts

IAG shares have surged over the past 18 months, but analysts are pointing to more growth. Dr James Fox takes…

Read more »